Search results
Showing 1396 to 1410 of 8314 results
Evidence-based recommendations on fremanezumab (Ajovy) for preventing migraine in adults.
Evidence-based recommendations on rimegepant (Vydura) for preventing migraine in adults.
Efgartigimod for treating antibody-positive generalised myasthenia gravis (TA1069)
Evidence-based recommendations on efgartigimod (Vyvgart) for treating antibody-positive generalised myasthenia gravis in adults.
Show all sections
Evidence-based recommendations on molnupiravir (Lagevrio) for treating mild to moderate COVID-19 in adults who have a positive SARS-CoV-2 test.
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)
Evidence-based recommendations on remdesivir (Veklury) and tixagevimab plus cilgavimab (Evusheld) for treating COVID-19.
Evidence-based recommendations on osimertinib (Tagrisso) with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer in adults.
Evidence-based recommendations on erdafitinib (Balversa) for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor in adults.
Show all sections
Evidence-based recommendations on brentuximab vedotin (Adcetris) for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma in adults.
Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts (TA399)
Evidence-based recommendations on azacitidine (Vidaza) for treating acute myeloid leukaemia with more than 30% bone marrow blasts.
Bosutinib for previously treated chronic myeloid leukaemia (TA401)
Evidence-based recommendations on bosutinib (Bosulif) for previously reated chronic myeloid leukaemia in adults.
Evidence-based recommendations on aflibercept (Eylea) for treating sight problems caused by diabetic macular oedema in adults.
Evidence-based recommendations on aflibercept (Eylea) for treating sight problems caused by macular oedema from central retinal vein occlusion in adults.
Mirabegron for treating symptoms of overactive bladder (TA290)
Evidence-based recommendations on mirabegron (Betmiga) for treating overactive bladder in adults.
Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)
Evidence-based recommendations on dapagliflozin (Forxiga) given with other drugs for treating type 2 diabetes in adults.
NICE is unable to make a recommendation about the use in the NHS of eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy. This is because Novartis did not provide an evidence submission
Show all sections
Sections for TA382